Healthcare -
Biotechnology - NASDAQ - US
$ 17.23
-2 %
$ 462 M
Market Cap
-110.87
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Eton Pharmaceuticals, Inc.
| Net Income | -3.82 M |
| Depreciation & Amortization | 1.15 M |
| Capital Expenditures | -26 K |
| Stock-Based Compensation | 3.16 M |
| Change in Working Capital | 0 |
| Others | 481 K |
| Free Cash Flow | 943 K |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||
| Net Income | (3.8) | (0.9) | (9.0) | (2.0) | (28.0) | (18.3) | (12.7) | (7.2) |
| Depreciation & Amortization | 1.1 | 0.9 | 1.8 | 0.5 | 0.7 | 0.4 | 63 K | 13 K |
| Deferred Income Tax | 0 | 0 | 0 | (0.5) | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 3.2 | 3.1 | 4.2 | 3.4 | 2.6 | 1.9 | 1.9 | 2.6 |
| Other Operating Activities | 0.5 | 0.1 | 0.1 | 0.1 | 1.4 | 16 K | 2.6 | 1.3 |
| Change in Working Capital | 0 | 3.6 | 7.7 | (6.2) | 1.0 | (2.1) | 99 K | 0.6 |
| Cash From Operations | 1.0 | 6.8 | 4.8 | (4.7) | (22.3) | (18.0) | (8.1) | (4.7) |
| INVESTING CASH FLOW | ||||||||
| Capital Expenditures | 26 K | (0.8) | (2.8) | (3.3) | 50 K | (1.8) | (0.2) | (0.1) |
| Other Items | (40.0) | 0 | 0 | 0.7 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (40.0) | (0.8) | (2.8) | (2.6) | 50 K | (1.8) | (0.2) | (0.1) |
| FINANCING CASH FLOW | ||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 24.2 | (1.2) | (0.4) | (0.1) | 2.5 | 4.8 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | (1.0) | 0 |
| Other Financing Activities | 1.4 | 0.2 | 0.3 | 0.5 | 0.4 | 0.5 | 0.2 | 18.0 |
| Cash From Financing Activities | 32.6 | (1.0) | (0.1) | 0.4 | 31.6 | 5.2 | 22.0 | 18.0 |
| CHANGE IN CASH | ||||||||
| Net Change In Cash | (6.5) | 5.1 | 1.9 | (6.9) | 9.2 | (14.7) | 13.6 | 13.2 |
| FREE CASH FLOW | ||||||||
| Free Cash Flow | 0.9 | 6.0 | 2.0 | (8.0) | (22.4) | (19.9) | (8.4) | (4.8) |